US Hospitals Will Restrict Lilly COVID-19 Antibody Treatment

US hospitals said on Tuesday they may limit the use of the new Eli Lilly antibody drug to COVID-19 patients with multiple risk factors for serious illness or to those patients whose immune systems have not begun to fight the infection.

US hospitals said on Tuesday they may limit the use of the new Eli Lilly antibody drug to COVID-19 patients with multiple risk factors for serious illness or to those patients whose immune systems have not begun to fight the infection.

“There will be a lot of pressure on physicians,” infectious disease specialist at the Cleveland Clinic and chair of the Infectious Diseases Society of America’s guidelines panel, Dr. Adarsh Bhimraj, told CNN Business, pointing out that the institution is still discussing its recommendations for the drug.

The treatment, bamlanivimab, was given US emergency use authorization last week by the US Food and Drug Administration for helping newly-diagnosed, high-risk patients avoid hospitalization.

According to the media outlet, medical groups and hospitals said they are working to establish criteria for which patients are likely to benefit most from the drug. “Otherwise, we will be out of drug real soon,” lung specialist at Houston Methodist Dr. Howard Huang said.

The FDA authorized bamlanivimab for patients over age 65 recently diagnosed with mild-to-moderate COVID-19 and patients risk factors such as obesity or diabetes. The agency said the drug should not be used in hospitalized patients.

“There may need to be some sort of composite score to select patients. Maybe we would use it for someone who has cardiovascular disease, and a history of stroke and is older?,” Huang said.


© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.